Clinical Trials Browser

Phase 1 × Trabedersen × Clear all

NCT00844064 2019-02-15

Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2

Phase 1 Completed

DermatologicGastrointestinal

Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms